Table 2 Adverse events
From: Camrelizumab for cancers in patients living with HIV: one-single center experience
No,(%) of patients | ≥Grade 3 | |
|---|---|---|
Any grade | ||
RCCEP | 20 (83%) | 1(4%) |
Hypothyroidism | 1 (4%) | 0 |
Asthenia | 2 (8%) | 0 |
Anaemia | 2 (8%) | 0 |
WBC count decreased | 3 (13%) | 0 |
Decreased appetite | 4 (17%) | 0 |
Diarrhoea | 1 (4%) | 0 |
Neutrophil count decreased | 2 (8%) | 0 |
Lymphocyte count decreased | 1 (4%) | 1(4%) |
Nausea | 5 (21%) | 0 |
Vomiting | 3 (13%) | 0 |
Hyponatraemia | 4 (17%) | 0 |
Lung infection | 1 (4%) | 0 |
Febrile neutropenia | 1 (4%) | 0 |
Death | 0 | 0 |